LOQTEQ® Antibacterial Pre-Market Study

计划入组 203 人 · 首次发布于 2022 年 3 月 2 日

Oldpain2go®: an Exploratory (Pre-Feasibility) Study.

计划入组 22 人 · 首次发布于 2019 年 1 月 15 日

Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe

计划入组 670 人 · 首次发布于 2025 年 12 月 15 日

PRE-084

PRE-103

X-Synergy®

GENOMIC HEALTH, INC.

United States

Theralase Technologies Inc

Canada

Natera

United States

Avacta Develops First Dual-Payload Peptide Drug Conjugate Platform for Cancer Combination Therapy

Avacta Therapeutics Raises £3.25 Million and Secures Bond Amendment to Advance FAP-Dox Cancer Therapy

Avacta Strengthens Leadership Team with Appointment of Chief Medical Officer and Business Development Advisor